Please login to the form below

Not currently logged in
Email:
Password:

cancer patients

This page shows the latest cancer patients news and features for those working in and with pharma, biotech and healthcare.

AZ, Daiichi Sankyo strengthen case for HER2 candidate

AZ, Daiichi Sankyo strengthen case for HER2 candidate

The phase 2 Destiny-Breast01 study investigated trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients, who had already received two or more prior HER2-targeting therapies. ... Its HER2CLIMB trial evaluated the drug as an add-on

Latest news

More from news
Approximately 0 fully matching, plus 1,025 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    For example, skin cancer patients who carry a BRAF V600 mutation are more likely to respond to BRAF inhibitors like Roche’s Zelboraf (Vemurafenib) than people without such mutations. ... In June 2018, Bristol Myers-Squibb sought approval for Opdivo and

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    findings in up to half of cancer patients. ... Of equal importance is support for patients and families, especially in reaching a correct diagnosis as early as possible.

  • Genomics integration: can the NHS rise to the challenge? Genomics integration: can the NHS rise to the challenge?

    Last year, NHS England announced that it will focus on earlier diagnosis and more personalised medicines for cancer and rare disease patients, and it will further that goal by launching a ... The data has to be managed very carefully, with the benefits

  • Bringing life to precision medicine Bringing life to precision medicine

    Thus far, researchers have been unable to identify which cancer drug will work most effectively for specific patients, ie, precision medicine. ... A groundbreaking study in 2018 on patients with recurrent metastatic cancer showed that organoids are

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    lung cancer NSCLC patients with low PD-L1 expression (1%, also without EGFR or ALK mutations) – a group that was once thought unlikely to benefit from these drugs. ... April. Naturally Merck &Co isn’t confining itself to dominance in lung cancer.

More from intelligence
Approximately 0 fully matching, plus 53 partially matching documents found.

Latest appointments

  • F-star hires ex-BMS immuno-oncology leader

    pipeline. As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the potential to improve the outcome for cancer patients has never ... He is an active member of the American Society of Clinical

  • New hires at Ferring, Flexion and Immunocore New hires at Ferring, Flexion and Immunocore

    It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell

  • BMS appoints new commercial leader, Davies joins Eisai and more BMS appoints new commercial leader, Davies joins Eisai and more

    Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as its chief medical and scientific officer. ... class new treatments for cancer patients and to help transform the company into a world-class

  • Sue Mahony to retire as president of Lilly Oncology Sue Mahony to retire as president of Lilly Oncology

    We make medicines that help patients with cancer live longer and what a privilege it’s been to wake up each morning with that as my life’s work.”.

  • José Baselga joins BMS’ board of directors José Baselga joins BMS’ board of directors

    Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and ... targeted cancer therapies and treating patients.

More from appointments
Approximately 0 fully matching, plus 32 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 64 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics